Ebola comes to NY; AstraZeneca drops antibiotics; FDA approves hemophilia A drug.
A highlight reel includes key moments from the Awards ceremony.
In a study to observe their effect in DTC ads, comparison claims in both print and video ads led consumers to trust those drugs over rival medications, researchers found.
Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.
The antipsychotic's hold on the market has been steady, despite generics of drugs such as AstraZeneca's Seroquel.
Researchers say the iPad app could help assess vision loss.
FDA panel endorses Novartis psoriasis drug; court rules with Pfizer on cancer drug patent; drugmakers may look for indemnity against losses from Ebola vaccines.
Despite strong performance by its MS therapies, the drugmaker's robust third-quarter sales were overshadowed by the death of a patient taking Tecfidera.The patient had a rare brain infection.
GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.
Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.
Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.
Novo partners with YouTube star for diabetes vids; hedge fund wants Amgen to split up; J&J ramps up Ebola vaccine production.
Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.
Researchers conclude that "more prominent warnings" are warranted for the class known as dopamine receptor agonists.
The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."
Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.
Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.
Promotions and hires for agencies and manufacturers
Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.
Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.
Suit alleges Purdue's OxyContin turned eastern Kentucky into "Wild West"; AbbVie-Shire $1.6B break-up fee could be tax write-off; Lilly CEO tells WSJ that 2014 has been "toughest year."
Perceptions of vaccines impact consumers' purchasing decisions
Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.
AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.
Pre-review documents indicate a favorable opinion of the IL-17 inhibitor secukinumab.
Resignations stymied the Office of Pharmaceutical Quality's beginning.
After 10 years of "Mucinex In. Mucus Out," the congestion-relief treatment gets a new look from Reckitt Beckinser's recently appointed AOR McCann New York.
AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung disease.
AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.
The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.
A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.
Jilted Salix acquisition target Cosmo Pharmaceutical is headed for the Emerald Isle.
AbbVie's board to reconsider Shire move; docs warm up to ACA; Eisai orphan thyroid cancer drug receives Priority Review.
Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.
The FDA will vote for or against the breast cancer drug by April 13, 2015.
Ireland plans on closing off a tax advantage but pharma does not appear to flinch.
BMS, Janssen and Pharmacyclics to test Opdivo/Imbruvica pairing; Google's latest health experiment will connect docs and patients over video-conferencing Hangouts tool; Five Ranbaxy execs resign after generics firm was acquired by Sun.
The sofosbuvir-ledipasvir combo is expected to run the average genotype 1 patient $80,000.
FDA commissioner Hamburg says agency wants to hasten medical device approvals; Amgen nets priority review for Phase-II leukemia drug; Novartis employee pleads guilty to bribery allegations.
Solutions for how to handle specialty medication costs are lacking, but the data around them shows a need for serious problem-solving.
The company is working with the FDA on new clinical trial requirements.
The ACLU is among those questioning the positives of the rumored healthcare effort.
Endo to acquire Auxilium for an estimated $2.6bn; Novartis says good-bye to three execs; NIH opens wallet for rare disease research; CMS's Open Payments show financial disparity between men and women; Clarient and GSK collaborate in cancer testing.
In an estimated $30-million deal, Pennsylvania healthcare comms agency Cadient Group is to be acquired by tech consultancy Cognizant.
The company says ABP 510 hit its primary endpoint in an adalimumab comparison.
In short: more antibotic prescriptions are written in the afternoon than in the morning.
The US Preventive Services Task Force wants adults at risk for type 2 diabetes to get tested.
Cadient is being acquired by consultancy Cognizant; Valeant ups the ante in Allergan bid; BMS settles Sustiva patent suits; Americans are dying at a lesser rate; Stricter Ebola screening at aiprorts.
Two cardiology associations advise prescribing Brilinta over Plavix for management of acute chest pain without electrocardiogram changes.
The drugmaker is poised to cut 14 pipeline projects loose.
The acquisition is meant to bolster the WPP agency's payer and market-access capabilities.
Cigna said found paying for medications and hospitalizations were top healthcare concerns.
Pfizer settles Chantix litigation; BMS scales back HCV efforts; FDA defends Zohydro approval.
Recent research suggests nurse practitioners and physicians assistants have a growing appetite for digital patient resources from industry.
Genentech's decision to pare access to three breast cancer drugs has spurred hospitals to take action.
Two regulatory agencies have rejected the drug, but analysts indicate the pipeline acute heart failure treatment could have limited market success.
An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.
Sources indicate Facebook is looking to dive into the social healthcare space.
Novartis BMS collaboration to evaluate Opdivo paired with three lung cancer treatments; Forbes weighs in on 60 Minutes segment; Sanofi management disagreements delay established drug portfolio sale; FDA sets price for Rare Pediatric Disease Priority Review vouchers; the GPhA challenges lawmakers' misconceptions of generic drug prices.
Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep
The results are in! Here are the Gold and Silver Award winners from the 2014 MM&M Awards:
Eli Lilly said it discontinued tabalumab, a drug being tested in Phase-III trials for lupus, after it failed to outperform the standard of care.
Government, charities spur production of Ebola treatment Zmapp; Venture capital likes digital health this year; Eli Lilly abandons lupus drug after disappointing Phase-III trial.
A survey shows sales rep bans are accelerating, while also pointing to a limited-time opportunity for pharma to become a significant partner for healthcare systems.
Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.
Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.
Ebola lands in the US; CMS's Open Payments database shows docs received $3.5 billion in last five months of 2013; Endo pays over $400 million to settle vaginal mesh suits.
The drugmaker is debuting a DTC campaign for the older constipation drug, despite a crowded therapeutic category and potential generics on the horizon.
A survey shows fewer payers expect more restrictive policies in the near-term.
The reveal comes days before hydrocodone products jump to a more restrictive access tier.
New Pfizer Viagra ads bring women into limelight; Open Payments database debuts to criticism; AbbVie/Shire deal set to be completed.
Late-stage immunotherapy results presented at a European medical conference over the weekend were heralded by clinicians, as AstraZeneca's lung-cancer darkhorse showcased strong early-stage results.
The FDA's Office of Prescription Drug Promotion says Pacira's promotional materials for Exparel are "extremely concerning," but the drugmaker tells investors the fuss is probably because opioids have been getting a lot of attention lately.
Promotions and hires for agencies and manufacturers
Mobile health devices may be more than they appear to be—consumers are taking an open-source approach to getting the monitors they want.
Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.
US government looks for alternative, nondrug, pain relief options for veterans; Gilead's HCV combo scores positive opinion in EU; FDA reopens commentary for social media draft guidance.
There are similarities between the 2014 formularies and their commercial counterparts. However, differences in the drug benefit designs show the predominance of four to five tiers, higher deductibles and higher copays or coinsurance levels compared to commercial benefits.
Shire pays $56-million fine to resolve improper ADHD marketing claims; FDA updates Chantix labeling to reflect new safety studies; GSK names new chairman.
Two FDA guidance documents on how health product manufacturers may participate in social media have each drawn criticism from affected industry and consumer groups.
MyStar Connect—available in Europe—translates glucose readings into actionable graphics.
The all-cash deal gives Acorda access to an experimental inhaled Parkinson's treatment that is meant to help patients when medication levels dip and symptoms surface.
Final guidance will float in around January, but the news puts Janssen and AbbVie on notice.
The reason: opioids.
Lightbulb company Royal Philips is swapping its heritage for the consumer healthcare business.
Pfizer tries to acquire Actavis; PhRMA says FDA social media rules are bad for consumers; US diabetes rates begin to slow.
The Treasury announced Monday it would eliminate certain techniques companies use to facilitate so-called tax inversions, which a number of drug companies have undertaken in the past six months.
The drugmaker says the Phase-I monoclonal antibody has three distinct mechanisms of action.
The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.
Treasury Department takes action against corporate tax inversions; CDC pegs Ebola worst case scenario at 1.4 million infected by new year; NIH allocates $10 million in grants to increase female clinical trials.
The Office of Prescription Drug Promotion took aim at Cipher Pharmaceuticals and its marketer Kowa, in an Untitled Letter over an e-mail alert making what it said were unsubstantiated assertions.
The bill proposes fining branded drugmakers for not complying.
The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.
GSK releases polio-infected water into Lasne River in Belgium; House reps Burgess and Schwartz introduce CME exemption bill for Sunshine Act; NIH and FDA announce plan to create facebook-esque catalogue of oral-drugs.
Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.
An FDA advisory panel voted overwhelmingly against the use of testosterone-replacement drugs for "low-T" Wednesday, saying the label should narrow and that more safety information is needed.
Merck unveiled the DPP-IV clinical trial results at the European Association for the Study of Diabetes Annual meeting Thursday.
FDA panel votes overwhelmingly against Low-T drugs; Stenda approved for fast-acting ED treatment; and Bayer hones life-sci focus, spins off material sciences business.
A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.